Cinda is showing off!

As the leading Biotech in China, Cinda Biotech has realized the commercialization of 5 products in ten years, and the sixth commercialized product is about to be born

PD-1 sold 1.

Recently, Cinda Bio's PD-1 sales have been disclosed, 2021H1 Daboshu (sintilimab injection) has sales of more than 1.

BeiGene and Hengrui Pharmaceutical also disclosed the sales of PD-1 in their semi-annual reports.

Daboshu (sintilimab injection) is an innovative PD-1 inhibitor jointly developed by Eli Lilly and Innovent in China, and this cooperation has now expanded to the global market

In the first half of 2021, Sintilimab injection was approved for three new first-line indications, including first-line non-squamous non-small cell lung cancer, first-line squamous non-small cell lung cancer and first-line hepatocellular carcinoma

At present, the indications of Sintilimab injection are still being expanded.

It is reported that Cinda Bio has a total production capacity of 24.

With the expansion of production capacity, the approval of new indications and the development of overseas markets, Sintilimab's sales are expected to increase

Commercialization of 5 products, attacking over 26 billion tinib drug market

2021 is the tenth year of Cinda Bio's establishment.

Thanks to the rapid year-on-year growth of the flagship product Daboshu and the significant revenue contribution from four newly-listed drugs, Cinda Bio will achieve product revenue of 1.

Cinda Biocommercial Products

Pemigatinib is a selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with Best-in-Class potential

It is worth mentioning that Cinda Bio is expected to usher in the sixth commercial product-IBI-348 (Olverembatinib) this year

Cinda's biological product pipeline has published 3 tinib drugs, including Pemigatinib, Olverembatinib and Taletrectinib

Protein kinase inhibitors (tinib drugs) are currently one of the research and development areas that domestic pharmaceutical companies are keen on, and their market growth potential is huge

Sales of terminal protein kinase inhibitors in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.

21 new class 1 drugs are under development! Monoclonal antibodies, double antibodies, and CAR-T are all deployed

Cinda Bio is committed to becoming a global biopharmaceutical company.
In 2021H1, the company invested 1.
042 billion yuan in research and development, an increase of 29.
0% year-on-year, mainly for the development of pipeline products in the company's later development stage and the global development of priority products under research
.

According to data from Meinenet, in addition to products that have been commercialized or submitted for NDA, Innovent has 22 new drugs in the clinical stage in China, of which 21 are Class 1 new drugs, involving diseases such as tumors, metabolism, immunity, and fundus diseases.
There are layouts for popular targets such as CD47, LAG-3 and TIGIT
.

Among the 22 products, only 3 Class 1 new drugs such as IBI376, IBI344 and IBI362 are small molecule chemical drugs, and the rest are macromolecular biological drugs, covering the fields of monoclonal antibodies, double antibodies and CAR-T.
Many products have First- In-Class or Best-in-Class potential
.

Cinda Bio is mainly researching new drugs

IBI322 (PD-L1/CD47), IBI318 (PD-1/PD-L1), IBI315 (PD-1/HER2), IBI321 (PD-1/TIGIT), IBI319 (PD-1/4-1BB) and IBI323 (LAG-3/PD-L1) and other 6 double antibodies are in phase I clinical stage
.
Among them, IBI-322 is the first PD-L1/CD47 double antibody to enter the clinical stage in the world
.

5 products in critical Phase II / III clinical stages, including IBI310, IBI376 (Parsaclisib), IBI326 , IBI344 (Taletrectinib), IBI306 and so on
.
Among them, IBI-376 and IBI-326 will submit NDA applications from the end of 2021 to early 2022.
IBI-376 is used to treat relapsed or refractory follicular lymphoma/marginal zone lymphoma, and is a potential best-in-class PI3Kδ inhibitor; IBI -326 is used for the treatment of relapsed or refractory multiple myeloma, and is potentially best-in-class BCAR CAR-T
.

Data source: Mi Nei.
com database, company announcement